Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

被引：0
|
作者：
Muggia, F. M. [1 ,2 ]
Boyd, L. [1 ,2 ]
Liebes, L. [1 ,2 ]
Downey, A. [1 ,2 ]
Muller, C. [1 ,2 ]
Pothuri, B. [1 ,2 ]
Blank, S. [1 ,2 ]
Rutledge, T. [1 ,2 ]
Fishman, D. [1 ,2 ]
Verschraegen, C. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5548
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT
    Boers-Sonderen, Marye J.
    de Geus-Oei, Lioe-Fee
    Desar, Ingrid M. E.
    van der Graaf, Winette T. A.
    Oyen, Wim J. G.
    Ottevanger, Petronella B.
    van Herpen, Carla M. L.
    TARGETED ONCOLOGY, 2014, 9 (04) : 339 - 347
  • [42] Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT
    Marye J. Boers-Sonderen
    Lioe-Fee de Geus-Oei
    Ingrid M. E. Desar
    Winette T. A. van der Graaf
    Wim J. G. Oyen
    Petronella B. Ottevanger
    Carla M. L. van Herpen
    Targeted Oncology, 2014, 9 : 339 - 347
  • [43] Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
    Walsh, M. D.
    Giovinazzo, H.
    Sheikh, A.
    Ivanovic, M.
    Whitlow, A. B.
    Newman, S. E.
    La-Beck, N. M.
    Kowalsky, R. J.
    Zamboni, B. A.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
    Xenidis, Nikolaos
    Vardakis, Nikolaos
    Varthalitis, Ioannis
    Giassas, Stylianos
    Kontopodis, Emmanouel
    Ziras, Nikolaos
    Gioulbasanis, Ioannis
    Samonis, George
    Kalbakis, Kostas
    Georgoulias, Vassilis
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 63 - 68
  • [45] PROLONGED TREATMENT WITH TRABECTIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) COMBINATION IN A HEAVILY PRETREATED PATIENT WITH METASTATIC RELAPSED OVARIAN CANCER (ROC)
    Guillet, P.
    Beedassy, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1369 - 1369
  • [46] Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
    Nikolaos Xenidis
    Nikolaos Vardakis
    Ioannis Varthalitis
    Stylianos Giassas
    Emmanouel Kontopodis
    Nikolaos Ziras
    Ioannis Gioulbasanis
    George Samonis
    Kostas Kalbakis
    Vassilis Georgoulias
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 63 - 68
  • [47] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC)
    Kim, Kenneth H.
    Jelovac, Danijela
    Armstrong, Deborah Kay
    Weil, Susan
    Phillips, Martin
    Schwartz, Benjamin M.
    Estes, Jacob Michael
    Alvarez, Ronald David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
    Jelovac, D.
    Armstrong, D. K.
    Weil, S.
    Phillips, M.
    Schwartz, B. M.
    Estes, J. M.
    Alvarez, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone
    Krasner, Carolyn N.
    Poveda, Andres
    Herzog, Thomas J.
    Vermorken, Jan B.
    Kaye, Stanley B.
    Nieto, Antonio
    Lardelli Claret, Pilar
    Park, Youn Choi
    Parekh, Trilok
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 161 - 167
  • [50] Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
    Pignata, Sandro
    Scambia, Giovanni
    Savarese, Antonella
    Breda, Enrico
    Scollo, Paolo
    De Vivo, Rocco
    Rossi, Emanuela
    Gebbia, Vittorio
    Natale, Donato
    Del Gaizo, Filomena
    Naglieri, Emanuele
    Ferro, Antonella
    Musso, Pietro
    D'Arco, Alfonso Maria
    Sorio, Roberto
    Pisano, Carmela
    Di Maio, Massimo
    Signoriello, Giuseppe
    Annunziata, Annalisa
    Perrone, Francesco
    BMC CANCER, 2006, 6 (1)
12345